N/A
N=2,004
The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)
Chronic Obstructive Pulmonary Disease (COPD)
Bottom Line
View on ClinicalTrials.gov: NCT03583099 ↗Enrolled (actual)
2,004
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD — 45.9; 41.9 percent — p=0.47
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- COPD plus CAPTURE education and patient-level information (Other); COPD Education Only (Other)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- Weill Medical College of Cornell University
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD |
45.9; 41.9 | 0.47 |
| SECONDARY Proportion of CAPTURE+ Participants Who Are Referred for or Complete Clinical Spirometry Testing |
30.0; 19.6 | 0.05 |
| SECONDARY Proportion of CAPTURE+ Participants Who Are Newly Diagnosed With COPD |
13.7; 12.4 | 0.75 |
| SECONDARY Proportion of CAPTURE+ Participants With Newly Prescribed Respiratory Medication |
25.2; 27.9 | 0.54 |
| SECONDARY Proportion of CAPTURE+ Participants Referred to a Specialist for Respiratory Evaluation/Treatment |
17.4; 12.3 | 0.16 |
| SECONDARY Proportion of CAPTURE+ Participants Who Are Referred for or Complete Pulmonary Rehabilitation |
6.40; 7.00 | 0.82 |
| SECONDARY Proportion of CAPTURE+ Participants Who Have Received a Recommendation for, or Administration of Influenza Vaccination. |
84.5; 90.8 | 0.06 |
| SECONDARY Proportion of CAPTURE+ Participants Smoking at the Baseline With Any Components of the Primary Endpoint OR Any of the 4 Events Described in the Description Below. |
83.37; 85.90 | 0.68 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Referred for or Complete Clinical Spirometry Testing |
37.52; 24.19 | 0.19 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a New Diagnosis of COPD |
24.62; 23.77 | 0.93 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Newly Prescribed Respiratory Medication |
37.05; 30.22 | 0.45 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Specialist for Respiratory Evaluation/Treatment |
21.58; 13.98 | 0.41 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral for, or Complete Pulmonary Rehabilitation. |
12.01; 10.16 | 0.81 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive Clinician Counseling or Recommendation for Smoking Cessation |
71.98; 63.96 | 0.51 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Smoking Cessation Program |
30.36; 40.70 | 0.41 |
| SECONDARY Proportion of CAPTURE+ Participants Capture Positive Participants Currently Smoking at Baseline Who Referral to a Smoking Quit Line |
55.60; 59.54 | 0.76 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Newly Prescribed Medication for Smoking Cessation. |
55.14; 55.90 | 0.95 |
| SECONDARY 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants |
-1.25; -0.93 | 0.55 |
| SECONDARY Proportion of CAPTURE+ Participants Who Experience Exacerbations. |
23.9; 15.3 | 0.05 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Who Meet Any of the Components of the Primary Endpoint. |
50.05; 48.25 | 0.88 |
| SECONDARY Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Clinical Spirometry Testing |
17.42; 23.04 | 0.53 |
| SECONDARY Proportion of Participants With Clinically Significant COPD With a New Diagnosis of COPD |
24.26; 13.58 | 0.24 |
| SECONDARY Proportion of Participants With Clinically Significant COPD With a Newly Prescribed Respiratory Medication |
24.87; 38.42 | 0.19 |
| SECONDARY Proportion of Participants With Clinically Significant COPD With a Referral to a Specialist for Respiratory Evaluation/Treatment |
10.14; 9.76 | 0.95 |
| SECONDARY Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Pulmonary Rehabilitation. |
5.63; 12.61 | 0.14 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Who Receive a Recommendation for or Administration of Influenza Vaccination |
93.22; 94.28 | 0.87 |
| SECONDARY Proportion of Participants With Spirometric COPD Who Meet Any of the Components of the Primary Endpoint. |
34.5; 36.2 | 0.81 |
| SECONDARY Proportion of Participants With Spirometric COPD Referred for or Completion of Clinical Spirometry Testing |
17.4; 15.1 | 0.63 |
| SECONDARY Proportion of Participants With Spirometric COPD With a New Diagnosis of COPD. |
15.9; 10.1 | 0.17 |
| SECONDARY Proportion of Participants With Spirometric COPD With Newly Prescribed Respiratory Medication |
19.8; 22.7 | 0.58 |
| SECONDARY Proportion of Participants With Spirometric COPD Referred to a Specialist for Respiratory Evaluation/Treatment |
7.6; 8.1 | 0.89 |
| SECONDARY Proportion of Participants With Spirometric COPD Who Are Referred for or Complete Pulmonary Rehabilitation. |
4.0; 7.8 | 0.16 |
| SECONDARY Proportion of Participants With Spirometric COPD Who Receive a Recommendation for or Administration of Influenza Vaccination. |
87.6; 89.8 | 0.62 |
| SECONDARY Proportion of Participants With Mild COPD Who Meet Any of the Components of the Primary Endpoint |
27.02; 28.66 | 0.84 |
| SECONDARY Proportion of Participants With Mild COPD Referred for or Completion of Clinical Spirometry Testing |
17.25; 11.16 | 0.27 |
| SECONDARY Proportion of Participants With Mild COPD With a New Diagnosis of COPD |
11.36; 8.45 | 0.55 |
| SECONDARY Proportion of Participants With Mild COPD With a Newly Prescribed Respiratory Medication |
17.29; 14.92 | 0.69 |
| SECONDARY Proportion of Participants With Mild COPD Referred to a Specialist for Respiratory Evaluation/Treatment |
5.89; 5.53 | 0.93 |
| SECONDARY Proportion of Participants With Mild COPD Referred for or Completion of Pulmonary Rehabilitation. |
3.49; 7.50 | 0.26 |
| SECONDARY Proportion of Participants With Mild COPD Who Received a Recommendation or Administration of Influenza Vaccination. |
85.04; 87.07 | 0.74 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Meet Any of the Components of the Primary Endpoint. |
30.4; 30.4 | 0.98 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Clinical Spirometry Testing. |
18.5; 15.9 | 0.46 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With New Diagnosis of COPD. |
7.4; 5.8 | 0.50 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With a Newly Prescribed Respiratory Medication |
17.4; 17.5 | 0.96 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred to a Specialist for Respiratory Evaluation/Treatment |
13.4; 11.2 | 0.40 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Pulmonary Rehabilitation. |
4.4; 4.6 | 0.96 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Receive a Recommendation for or Administration of Influenza Vaccination. |
85.2; 85.1 | 0.98 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Meet Any of the Components of the Primary Endpoint. |
28.4; 32.6 | 0.46 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Clinical Spirometry Testing. |
18.8; 14.9 | 0.37 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) With a New Diagnosis of COPD |
4.8; 5.7 | 0.75 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Newly Prescribed Respiratory Medication |
12.3; 21.0 | 0.08 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred to a Specialist for Respiratory Evaluation/Treatment |
6.0; 10.8 | 0.11 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Pulmonary Rehabilitation. |
5.4; 5.0 | 0.89 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Who Receive a Recommendation or Administration of Influenza Vaccination. |
80.4; 89.1 | 0.05 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
52.81; 36.04 | 0.09 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
45.7; 42.0 | 0.56 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing |
28.86; 18.45 | 0.49 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing |
30.4; 19.6 | 0.06 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Newly Diagnosed With COPD |
13.11; 12.70 | 0.94 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Newly Diagnosed With COPD |
14.8; 12.1 | 0.57 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication |
24.15; 22.79 | 0.89 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication |
26.1; 28.4 | 0.65 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
19.78; 7.30 | 0.16 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
16.9; 12.7 | 0.29 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation |
11.34; 6.06 | 0.44 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation |
5.2; 6.8 | 0.62 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination |
88.30; 95.39 | 0.39 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination |
83.3; 89.9 | 0.08 |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Have Received a Recommendation for, or Administration of Influenza Vaccination |
71.66; 82.70 | 0.23 |
| SECONDARY 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled Before March 20, 2019 |
-2.44; -1.30 | 0.97 |
| SECONDARY 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled on or After March 20, 2019 |
-0.92; -0.92 | 0.47 |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Exacerbations. |
26.62; 8.78 | 0.02 sig |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Exacerbations. |
23.7; 15.9 | 0.12 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Meet Any of Components of the Primary Endpoints. |
42.8; 0 | 1.0 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 Who Meet Any of Components of the Primary Endpoints. |
51.76; 49.69 | 0.87 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing |
14.3; 0 | 1.0 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing |
18.14; 23.66 | 0.56 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD |
14.3; 0 | 1.0 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 a New Diagnosis of COPD |
26.62; 13.96 | 0.21 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication |
42.8; 0 | 1.0 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication |
21.04; 39.33 | 0.08 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment |
14.3; 0 | 1.0 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment |
9.31; 9.98 | 0.92 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation |
0; 0 | — |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation |
6.54; 12.02 | 0.29 |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description) |
100; 100 | — |
| SECONDARY Proportion of Participants With Clinically Significant COPD Enrolled After August 13, 2020 Who Receive a Recommendation for or Administration of Influenza Vaccination |
91.13; 94.00 | 0.69 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint |
16.03; 29.18 | 0.32 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint |
37.0; 37.2 | 0.98 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description) |
NA; 0 | — |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
19.3; 16.2 | 0.55 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD |
5.10; 13.71 | 0.43 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD |
17.5; 9.9 | 0.10 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication |
15.75; 14.93 | 0.94 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication |
20.1; 23.5 | 0.55 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment (Abbreviated as Proportion in the Description) |
NA; 0 | — |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
7.6; 8.7 | 0.80 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation |
0; 0 | — |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation |
4.5; 8.4 | 0.18 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination |
88.25; 88.42 | 0.99 |
| SECONDARY Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination |
87.5; 90.1 | 0.59 |
| SECONDARY Proportion of Mild COPD Participants Enrolled Before 3/20/2019 With Any of :1) Clinical Spirometry Referral, 2) New COPD Diagnosis, 3) Newly Prescribed Respiratory Medication, 4) Respiratory Specialist Referral, 5) Referral/Completion of Pulmonary Rehab |
0; NA | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint |
30.8; 28.9 | 0.82 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description) |
0; 0 | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
20.1; 12.5 | 0.20 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description) |
0; NA | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD |
12.8; 7.9 | 0.36 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication (Abbreviated as Proportion in the Description) |
0; NA | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication |
19.6; 15.0 | 0.47 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
0; 0 | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
6.7; 6.1 | 0.88 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
0; 0 | — |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
4.0; 8.2 | 0.27 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination |
77.75; 82.7 | 0.82 |
| SECONDARY Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination |
86.3; 87.4 | 0.87 |
| SECONDARY Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
29.03; 66.7 | 0.03 sig |
| SECONDARY Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
31.2; 28.8 | 0.56 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
18.21; 41.27 | 0.06 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
17.6; 14.4 | 0.39 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With New Diagnosis of COPD |
7.33; 9.05 | 0.84 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With New Diagnosis of COPD |
7.5; 5.5 | 0.42 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication |
13.17; 55.27 | 0.01 sig |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication |
18.3; 15.8 | 0.47 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
17.60; 29.87 | 0.34 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
12.6; 10.2 | 0.39 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
NA; 0 | — |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
3.5; 4.7 | 0.59 |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description) |
NA; 100 | — |
| SECONDARY Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination |
84.7; 84.3 | 0.94 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
35.8; 35.2 | 0.93 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint. |
25.5; 33.7 | 0.25 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
21.7; 25.1 | 0.48 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing |
17.1; 13.1 | 0.45 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description) |
NA; 0 | — |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 With a New Diagnosis of COPD |
4.4; 6.7 | 0.48 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Newly Prescribed Respiratory Medication |
14.8; 15.2 | 0.97 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Newly Prescribed Respiratory Medication |
10.6; 22.7 | 0.04 sig |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
8.1; 9.9 | 0.39 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment |
4.5; 11.7 | 0.06 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
4.1; 5.0 | 0.82 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation |
6.2; 5.6 | 0.86 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination. |
87.4; 94.8 | 0.14 |
| SECONDARY Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination. |
77.0; 88.2 | — |
| SECONDARY Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Received Over-the-counter Patches/Gum for Smoking Cessation |
41.52; 56.18 | 0.21 |
| SECONDARY Proportion of CAPTURE+ Participants Who Experience Hospitalizations |
4; 2; 221; 158; 1; 1 | 0.76 |
| SECONDARY Number of Enrolled CAPTURE+ Participants Who Experience Mortality |
2; 2 | — |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Hospitalizations |
0.0; 0.0 | — |
| SECONDARY Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Hospitalizations |
2.1; 1.5 | 0.66 |
| SECONDARY Number of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Mortality. |
0; 0 | — |
| SECONDARY Number of CAPTURE+ Participants Enrolled After March 20, 2019 Who Experience Mortality. |
2; 2 | — |
Summary
A prospective, multicenter study including a cross-section validation to define sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant Chronic Obstructive Pulmonary Disease (COPD), and its impact on clinical care across a broad range of primary care settings in a cluster randomized controlled clinical trial.
Eligibility Criteria
Inclusion Criteria
- 1. Provision of signed and dated informed consent form
- 2. Stated willingness to comply with all study procedures and availability for the duration of the study
- 3. Male or female, aged 45 - 80 years
- 4. Able to read and speak English or Spanish
Exclusion Criteria
- 1. Previous clinician provided diagnosis of COPD
- 2. Treated respiratory infection (with antibiotics and/or systemic steroids) in the past 30 days
- 3. Participants unable to perform spirometry due to any of the following conditions within the past 30 days
- Chest surgery
- Abdominal surgery
- Eye surgery
- Heart attack
- Stroke
Data sourced from ClinicalTrials.gov (NCT03583099). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.